The World Health Organization (WHO) emergency use of AstraZeneca and Oxford University’s COVID-19 vaccines on Monday, expanding access to relatively inexpensive injections in developing countries.
“We now have all the parts for rapid vaccine distribution. But we still have to increase production,”said Tedros Adhanom Gebreesus, Director General of WHO, in a press conference.
“We continue to urge the COVID19 vaccine developers to submit their files to WHO for review. And also to be submitted to regulators in high-income countries,” he said in addition.
Vaccines made by AstraZeneca-SKBio (Republic of Korea) and Serum Institute of India have approved in a WHO statement.
“We hope that more than 300 million doses of vaccine will be delivered via COVAX in 145 countries by the first half of 2021 to meet the challenges of treatment and surgery,” said the British drugmaker in a separate statement.
The list of UN health agencies comes days after a WHO panel made initial recommendations for the vaccine. Hence, all adults should receive two doses, approximately 8 to 12 weeks apart, which can be used in South African countries. Corona virus variant too.
A WHO review found Astrazeneca met mandatory safety criteria and that the benefits of its effectiveness outweigh the risks.
The COVAX Division Program
The AstraZeneca / Oxford shot was welcomed because it was cheaper and easier to distribute than several competitors, including Pfizer / BioNTech, which was added to the WHO emergency list in late December.
“Nearly 109 million people worldwide has infected with the new coronavirus, and more than 2.5 million have died”. Infections have reported in more than 210 countries and territories. Since the first cases were discovered in China in December 2019.
The AstraZeneca vaccine is the largest share of the dose in the COVAX coronavirus vaccine sharing initiative. By the end of February, more than 330 million syringe cans will be used in poor countries.
WHO has created an Emergency Use List (EUL) to help poor countries without their own regulatory resources. In this case, quickly approve drugs for new diseases like COVID-19, which could lead to delays.
The COVAX instrument, led by GAVI, the World Health Organization, the Coalition for Epidemic Preparation for Innovation. And the United Nations Children’s Fund, says that the dose will cover an average of 3.3% of the total population of the 145 participating countries.